Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 17, 2018
Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
HOPKINTON, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
September 17, 2018
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
AUSTIN, Texas, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
September 17, 2018
Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally ...
September 17, 2018
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018/PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data ...
September 12, 2018
Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, ...
September 12, 2018
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 12, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
September 12, 2018
Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date
VANCOUVER, Sept. 12, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies ...
September 12, 2018
Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects
BUFFALO, N.Y., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
September 12, 2018
PolarityTE, Inc. Reports Financial Results and Corporate Update for Quarter End July 31, 2018
SALT LAKE CITY, Sept. 12, 2018 /PRNewswire/ -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients ...
September 12, 2018
Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 (Copper Histidinate) for Menkes Disease in Molecular Therapy: Methods & Clinical Development
NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and ...
September 12, 2018
BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform
NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics ...
September 11, 2018
OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104, CD28-Antagonist Immunotherapy
NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), has strengthened its intellectual property rights for the developmental product ...
September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation ...
September 11, 2018
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018/PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that new ...
September 11, 2018
Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
September 10, 2018
Innate Pharma announces data presentations at upcoming scientific meetings
Marseille, France, September 10, 2018, Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that updated data from ongoing clinical trials evaluating ...
September 10, 2018
Sensorion to Partner with Vestibular Disorders Association (VeDA) in Sponsorship of Balance Awareness Week 2018 for Vestibular Disorders
MONTPELLIER, France, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sensorion(FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that ...
September 10, 2018
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living with ...
September 10, 2018
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological ...
September 10, 2018
TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
Page 52 of 150